The importance of the role of HER3 is further exemplified in the study by Garrett et al where HER3 was upregulated in breast tumours after inhibition of HER2 with lapatinib, but where inhibition of HER3 sensitized HER2-positive breast cancer cells to lapatinib[59]. Here, ERBB3 is linked to breast neoplasm.